Prothena Corp. (PRTA) Tops Q1 EPS by 40c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update
May 9, 2017 4:06 PM EDTNet cash used in operating and investing activities was $40.2 million in the first quarter; quarter-end cash and restricted cash position of $510.6 million, including net proceeds of $150.3 million raised through March 2017 public equity offering, provides funding to advance R&D pipelineCompleted enrollment in the Phase 2b PRONTO study evaluating NEOD001 in previously treated patients with AL amyloidosis and persistent cardiac dysfunctionPresented results from the Phase 1b study of PRX002/RG7935 in an oral session at the 13th International Conference on Alzheimers and Parkinsons Disease (AD/PD)... More
